SEC Comment Letter 0000000000-23-001302 to CASI Pharmaceuticals, Inc. (CASI) (CIK 0001962738) (CASIF)

CASI Pharmaceuticals, Inc. (CASI) (CIK 0001962738)
Date: Feb. 8, 2023 · CIK: 0001962738 · Accession: 0000000000-23-001302

View on Edgar

AI Filing Summary & Sentiment

File numbers found in text: 333-269479

Date

February 8, 2023

Author

Not clearly detected

Form

UPLOAD

Company

CASI Pharmaceuticals, Inc. (CASI) (CIK 0001962738)

Letter

United States securities and exchange commission logo February 8, 2023 Wei Zhang President CASI Pharmaceuticals Holdings, Inc. 1701-1702, China Central Office Tower 1 No. 81 Jianguo Road Chaoyang District Beijing, 100025 People’s Republic of China Re:CASI Pharmaceuticals Holdings, Inc. Registration Statement on Form F-4 Filed on January 31, 2023 File No. 333-269479 Dear Wei Zhang: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Joshua Gorsky at 202-551-7836 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Peter X. Huang, Esq.

Show Raw Text

United States securities and exchange commission logo
February 8, 2023
Wei Zhang
President
CASI Pharmaceuticals Holdings, Inc.
1701-1702, China Central Office Tower 1
No. 81 Jianguo Road Chaoyang District
Beijing, 100025
People’s Republic of China
Re:CASI Pharmaceuticals Holdings, Inc.
Registration Statement on Form F-4
Filed on January 31, 2023
File No. 333-269479
Dear Wei Zhang:
            This is to advise you that we have not reviewed and will not review your registration
statement.
            Please refer to Rules 460 and 461 regarding requests for acceleration.  We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
            Please contact Joshua Gorsky at 202-551-7836 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:       Peter X. Huang, Esq.

SecProbe.io